The Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
NATHBIOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.4 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NSE has asked Nath Bio-Genes to clarify discrepancies found in the financial results filed in XBRL format for the quarter ended 30 June 2025, under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. The company has not yet submitted its response, which is still awaited. No further details on the nature of the discrepancies have been disclosed in this filing. This is a procedural clarification request rather than a punitive action at this stage.
Until the company clarifies the discrepancies, this adds short-term uncertainty around its Q1 FY26 reported numbers. It may dent investor confidence if the response is delayed or reveals material issues, but it carries no direct financial penalty or trading restriction yet.